Biotech firm Libra Therapeutics is developing treatments for neurodegenerative diseases and aims to start Phase 1 clinical trials in 2025. The San Diego-based virtual company, established in 2020, outsources its R&D to contract research organisations (CROs) and relies heavily on data management platform CDD Vault to enable the comparison of diverse data from its CRO partners. Martin Gill, Libra’s Vice President and Head of Biology, stated the company is aiming to be first and best in its class.
Alleged data breaches into Nottingham triple killer case ‘an utter disgrace’
Alleged inappropriate access of case files by prison and courts staff relating to triple killer, Valdo Calocane, has been labelled a “disgrace” by victims’ families.
